Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals6.06%+1.38 ppManaged Health Care2.75%+0.73 ppBiotechnology2.76%+0.64 ppHealth Care Distributors0.40%+0.11 ppHealth Care Supplies0.17%-0.11 ppHealth Care Equipment3.05%-0.11 ppHealth Care Services0.96%+0.10 ppHealth Care Facilities0.19%-0.05 ppLife Sciences Tools & Services2.10%-0.01 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.76%
Industry change · 12M
+0.64 pp
Biotechnology · contribution
+0.638 pp
Company participation
100%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Jun 2022 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $270.7bn | 1.053% | +0.087 pp | +0.350 pp | +41.8% | Yes |
| Moderna → MRNA | United States | $56.8bn | 0.221% | -0.013 pp | +0.221 pp | -39.2% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $72.1bn | 0.280% | +0.057 pp | +0.096 pp | +39.8% | Yes |
| Biogen → BIIB | United States | $29.9bn | 0.116% | +0.012 pp | -0.068 pp | -41.1% | Yes |
| Regeneron Pharmaceuticals → REGN | United States | $55.5bn | 0.216% | -0.005 pp | +0.031 pp | +5.8% | Yes |
| Amgen → AMGN | United States | $130.0bn | 0.505% | +0.052 pp | +0.011 pp | +3.1% | Yes |
| Gilead Sciences → GILD | United States | $77.5bn | 0.302% | +0.051 pp | -0.003 pp | -6.1% | Yes |
| Incyte → INCY | United States | $16.8bn | 0.065% | +0.006 pp | +0.000 pp | -9.7% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.